Laboratory of Tumor Immunology and Biology, CCR
National Cancer Institute
United States of America
Dr. Sofia Gameiro received her Ph.D. in Pharmaceutical Sciences from the State University of New York at Buffalo in 2008. She subsequently joined the NIH as a Postdoctoral Fellow in the Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, and was appointed as a Staff Scientist in 2017. Dr. Gameiro’s current research focuses on identifying and exploiting mechanisms through which anticancer agents can reprogram the immunosuppressive tumor microenvironment to allow for efficient immune-mediated elimination of cancer cells.
1) Cancer immunotherapy 2) immune modulation 3) identifying and exploiting immune mechanisms elicited by novel immunotherapeutics and emerging anticancer agents 4) Cancer Biology, 5) Immunology
Chemotherapy-induced immunogenic modulation of tumor cells enhances killing by cytotoxic T-lymphocytes and is distinct from immunogenic cell death.
Radiation-induced immunogenic modulation of tumor enhances antigen processing and calreticulin exposure, resulting in enhanced T-cell killing
Inhibitors of histone deacetylase 1 reverse the immune evasion phenotype to enhance T-cell mediated lysis of prostate and breast carcinoma cells.